Replacement Director/PDMR Shareholding

RNS Number : 8101W

GlaxoSmithKline PLC

03 February 2012

 



This announcement replaces the original announcement released on 1 July 2011 at 13.42 (RNS No: 6109J).

One of the Non-Executive Director's interests in the Ordinary shares of GlaxoSmithKline plc, indicated with an asterisk (*) below, was incorrectly stated in the announcement made on 1 July 2011.

Save as disclosed above, all other details remain unchanged. The full amended text is shown below.

 Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary shares and American Depository Shares (ADSs) of GlaxoSmithKline plc.

On 30 June 2011, the Company's Non-Executive Directors were provisionally allocated awards over Ordinary shares at a price of £13.20 per Ordinary share and $42.43 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2011 to 30 June 2011:

Non Executive Director	Ordinary Shares	American Depository Shares (ADSs)
Sir Christopher Gent	2,556.818
Prof. Sir Roy Anderson	639.205
Dr Stephanie Burns		488.684
Ms Stacey Cartwright	355.114
Mr Lawrence Culp		977.369
Sir Crispin Davis	2,367.424
Ms Judy Lewent		174.530
Sir Deryck Maughan		977.369
Mr James Murdoch	1,420.455*
Dr Daniel Podolsky		942.463
Mr Tom de Swaan	875.947
Sir Robert Wilson	639.205

The Company and the Non-Executive Directors were informed of these allocations on 1 July 2011.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte

Company Secretary

 

END

 

 

RDSFMGGZVFVGZZM